351 related articles for article (PubMed ID: 15869735)
1. Treatment of myeloma in patients not eligible for transplantation.
Jagannath S
Curr Treat Options Oncol; 2005 May; 6(3):241-53. PubMed ID: 15869735
[TBL] [Abstract][Full Text] [Related]
2. Treatment of multiple myeloma: 2009 update.
Prescrire Int; 2009 Dec; 18(104):263-6. PubMed ID: 20025098
[TBL] [Abstract][Full Text] [Related]
3. Bortezomib in the front-line treatment of multiple myeloma.
Richardson PG; Mitsiades C; Schlossman R; Ghobrial I; Hideshima T; Munshi N; Anderson KC
Expert Rev Anticancer Ther; 2008 Jul; 8(7):1053-72. PubMed ID: 18588451
[TBL] [Abstract][Full Text] [Related]
4. Sequential vincristine, adriamycin, dexamethasone (VAD) followed by bortezomib, thalidomide, dexamethasone (VTD) as induction, followed by high-dose therapy with autologous stem cell transplant and consolidation therapy with bortezomib for newly diagnosed multiple myeloma: results of a phase II trial.
Kim HJ; Yoon SS; Lee DS; Sohn SK; Eom HS; Lee JL; Chung JS; Kim K; Suh C; Won JH; Kim JS; Park JS; Kang HJ; Seong CM; Kim CS; Lee SJ; Lee JH
Ann Hematol; 2012 Feb; 91(2):249-56. PubMed ID: 21789621
[TBL] [Abstract][Full Text] [Related]
5. Induction therapy in multiple myeloma.
Harousseau JL
Hematology Am Soc Hematol Educ Program; 2008; ():306-12. PubMed ID: 19074101
[TBL] [Abstract][Full Text] [Related]
6. Shifts in the therapeutic paradigm for patients newly diagnosed with multiple myeloma: maintenance therapy and overall survival.
Palumbo A; Attal M; Roussel M
Clin Cancer Res; 2011 Mar; 17(6):1253-63. PubMed ID: 21411441
[TBL] [Abstract][Full Text] [Related]
7. The clinical effectiveness and cost-effectiveness of bortezomib and thalidomide in combination regimens with an alkylating agent and a corticosteroid for the first-line treatment of multiple myeloma: a systematic review and economic evaluation.
Picot J; Cooper K; Bryant J; Clegg AJ
Health Technol Assess; 2011 Dec; 15(41):1-204. PubMed ID: 22146234
[TBL] [Abstract][Full Text] [Related]
8. New treatments for multiple myeloma.
Richardson PG; Schlossman R; Hideshima T; Anderson KC
Oncology (Williston Park); 2005 Dec; 19(14):1781-92; discussion 1792, 1795-7. PubMed ID: 16506632
[TBL] [Abstract][Full Text] [Related]
9. Novel therapies in multiple myeloma for newly diagnosed nontransplant candidates.
Kristinsson SY; Landgren O; Rajkumar VS
Cancer J; 2009; 15(6):473-8. PubMed ID: 20010166
[TBL] [Abstract][Full Text] [Related]
10. [New treatment of multiple myeloma].
Hulin C
Rev Med Interne; 2007 Oct; 28(10):682-8. PubMed ID: 17559982
[TBL] [Abstract][Full Text] [Related]
11. The emerging role of novel therapies for the treatment of relapsed myeloma.
Richardson PG; Hideshima T; Mitsiades C; Anderson KC
J Natl Compr Canc Netw; 2007 Feb; 5(2):149-62. PubMed ID: 17335684
[TBL] [Abstract][Full Text] [Related]
12. Multiple myeloma: treatment evolution.
San Miguel JF; Mateos MV; Ocio E; Garcia-Sanz R
Hematology; 2012 Apr; 17 Suppl 1():S3-6. PubMed ID: 22507766
[TBL] [Abstract][Full Text] [Related]
13. New therapies in multiple myeloma.
Merchionne F; Perosa F; Dammacco F
Clin Exp Med; 2007 Sep; 7(3):83-97. PubMed ID: 17972050
[TBL] [Abstract][Full Text] [Related]
14. New treatments for myeloma.
Azaïs I; Brault R; Debiais F
Joint Bone Spine; 2010 Jan; 77(1):20-6. PubMed ID: 20031467
[TBL] [Abstract][Full Text] [Related]
15. Treatment of newly diagnosed myeloma.
Palumbo A; Rajkumar SV
Leukemia; 2009 Mar; 23(3):449-56. PubMed ID: 19005483
[TBL] [Abstract][Full Text] [Related]
16. [Treatment of AL amyloidosis in 2012; the benefit of new drugs (bortezomib, thalidomide, and lenalidomide). Summary of published clinical trials].
Adam Z; Sčudla V; Krejčí M; Cermáková Z; Pour L; Král Z
Vnitr Lek; 2013 Jan; 59(1):37-58. PubMed ID: 23428001
[TBL] [Abstract][Full Text] [Related]
17. Firstline treatment and maintenance in newly diagnosed multiple myeloma patients.
Roussel M; Facon T; Moreau P; Harousseau JL; Attal M
Recent Results Cancer Res; 2011; 183():189-206. PubMed ID: 21509686
[TBL] [Abstract][Full Text] [Related]
18. Treatment of multiple myeloma in the targeted therapy era.
Saad AA; Sharma M; Higa GM
Ann Pharmacother; 2009 Feb; 43(2):329-38. PubMed ID: 19193585
[TBL] [Abstract][Full Text] [Related]
19. Bortezomib in combination with thalidomide-dexamethasone for previously untreated multiple myeloma.
Wang M; Giralt S; Delasalle K; Handy B; Alexanian R
Hematology; 2007 Jun; 12(3):235-9. PubMed ID: 17558699
[TBL] [Abstract][Full Text] [Related]
20. (Bortezomib plus lenalidomide/thalidomide)- vs. (bortezomib or lenalidomide/thalidomide)-containing regimens as induction therapy in newly diagnosed multiple myeloma: a meta-analysis of randomized controlled trials.
Wang A; Duan Q; Liu X; Ding K; Han Y; Zhu W; Cai X; Wu J; Sun Z
Ann Hematol; 2012 Nov; 91(11):1779-84. PubMed ID: 22773209
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
